CN102994621B - PTPN11 gene mutation detection specificity primer and liquid chip thereof - Google Patents
PTPN11 gene mutation detection specificity primer and liquid chip thereof Download PDFInfo
- Publication number
- CN102994621B CN102994621B CN201110269795.2A CN201110269795A CN102994621B CN 102994621 B CN102994621 B CN 102994621B CN 201110269795 A CN201110269795 A CN 201110269795A CN 102994621 B CN102994621 B CN 102994621B
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- site
- tag
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 44
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 25
- 101150048674 PTPN11 gene Proteins 0.000 title claims abstract description 24
- 239000007788 liquid Substances 0.000 title claims abstract description 6
- 241000183024 Populus tremula Species 0.000 claims abstract description 38
- 102200155463 rs397507509 Human genes 0.000 claims abstract description 20
- 102200155477 rs397507511 Human genes 0.000 claims abstract description 20
- 102200155728 rs121918462 Human genes 0.000 claims abstract description 18
- 102200155470 rs397507510 Human genes 0.000 claims abstract description 18
- 102200155732 rs121918453 Human genes 0.000 claims abstract description 17
- 102200155721 rs121918464 Human genes 0.000 claims abstract description 16
- 239000007791 liquid phase Substances 0.000 claims description 27
- 230000000869 mutational effect Effects 0.000 claims description 20
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 9
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 abstract description 7
- 230000035772 mutation Effects 0.000 abstract description 6
- 239000004005 microsphere Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102200006614 rs104894229 Human genes 0.000 description 2
- 102220198275 rs121918454 Human genes 0.000 description 2
- 102200155726 rs121918465 Human genes 0.000 description 2
- 102200006648 rs28933406 Human genes 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a PTPN11 gene mutation detection specificity primer and a liquid chip thereof. The liquid chip mainly comprises: an ASPE primer composed of a 5'-terminal tag sequence and 3'-terminal specificity primer sequences focused on target gene mutation sites, wherein the specificity primer sequences comprise SEQ ID NO.24 and SEQ ID NO.25 focused on a G60V site, SEQ ID NO.26, SEQ ID NO.27 and SEQ ID NO.28 focused on a D61Y/V site, SEQ ID NO.29 and SEQ ID NO.30 focused on an E69K site, SEQ ID NO.31, SEQ ID NO.32 and SEQ ID NO.33 focused on an A72T/D site, SEQ ID NO.34 and SEQ ID NO.35 focused on a T73I site, SEQ ID NO.36, SEQ ID NO.37, SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40 and SEQ ID NO.41 focused on an E76K/Q/A/G/V site, SEQ ID NO.42 and SEQ ID NO.43 focused on an S502P site, and/or SEQ ID NO.44, SEQ ID NO.45 and SEQ ID NO.46 focused on a G503A/V site; a microsphere coated by an anti-tag sequence; and an amplimer. The consistency between the detection result of the detection liquid chip provided by the invention and the detection result of a sequencing method is high to 100%, and the wild-type and mutant parallel detection of a plurality of mutation sites is realized.
Description
Technical field
The invention belongs to biology field, relate to medical science and biotechnology, concrete a kind of PTPN11 detection in Gene Mutation Auele Specific Primer and the liquid-phase chip of relating to.
Background technology
Non-receptor type protein-tyrosine-phosphatase (protein-tyrosine phosphatase, nonreceptor-type 11, PTPN11), at present, the method of PTPN11 transgenation being carried out to determination and analysis is little, mainly contain direct sequencing and PCR-RFLP analytical method, wherein the most frequently used method has PCR-RFLP analytical method.PCR-RFLP method is the change of the restriction enzyme enzyme recognition site that causes based on transgenation, as lost or generation novel site in site, by a certain specific fragment of pcr amplification, use again digestion with restriction enzyme amplified production, the size of electrophoresis observation fragment, the transgenation that this method changes for detection of restriction enzyme site, can directly judge genotype, but this method can not be used for not producing the detection in Gene Mutation of new restriction enzyme site.Again, above these methods all exist the limitation that detects flux, can only detect a kind of mutation type at every turn, can not meet the needs of practical application.
Summary of the invention
One of object of the present invention is to provide PTPN11 gene mutation detection liquid-phase chip, and this liquid-phase chip can be with individual event or is listed in and detects 15 kinds of common genotype G60V, D61Y/V, E69K, A72T/D, T73I, the E76K/Q/A/G/V of PTPN11 gene 8 codons, wild-type type and the saltant type of S502P, G503A/V.
A kind of PTPN11 gene mutation detection liquid-phase chip, includes:
(A). the wild-type designing respectively for the different mutational sites of PTPN11 gene and the ASPE primer of saltant type: every kind of ASPE primer is made up of for the specific primer sequence in goal gene mutational site tag sequence and the 3 ' end of 5 ' end, and described specific primer sequence is: for SEQ ID NO.24 and the SEQ ID NO.25 in G60V site; For the SEQ IDNO.26 in D61Y/V site and be selected from SEQ ID NO.27 and SEQ ID NO.28 in one or more; For SEQ IDNO.29 and the SEQ ID NO.30 in E69K site; For the SEQ ID NO.31 in A72T/D site and be selected from SEQ ID NO.32 and SEQ IDNO.33 in one or more; For SEQ ID NO.34 and the SEQ ID NO.35 in T73I site; For the SEQ ID NO.36 in E76K/Q/A/G/V site and be selected from one or more in SEQ ID NO.37, SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40 and SEQ ID NO.41; For SEQ ID NO.42 and the SEQ ID NO.43 in S502P site; And/or for the SEQ ID NO.44 in G503A/V site and be selected from SEQ ID NO.45 and SEQ ID NO.46 in one or more; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.23;
(B). there is microballoon that anti-tag sequence is coated with, that there is different colours coding, in the middle of described anti-tag sequence is connected with microballoon, be also provided with spacerarm sequence; Described anti-tag sequence is selected from SEQ ID NO.47～SEQ ID NO.69, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). for amplifying the primer that needs the target sequence detecting, there is corresponding mutational site.
Preferably, described amplimer is: for SEQ ID NO.70～SEQ ID NO.71 in G60V, D61Y/V, E69K, A72T/D, T73I and/or E76K/Q/A/G/V site; For SEQ ID NO.72～SEQ IDNO.73 in S502P, G503A/V site.
Preferably, described ASPE primer is: the sequence forming for the sequence being made up of SEQ ID NO.1 and SEQ ID NO.24 in G60V site and SEQ ID NO.2 and SEQ ID NO.25; For the sequence being formed by SEQ ID NO.3 and SEQID NO.26 in D61Y/V site and select free SEQ ID NO.4 and sequence that SEQ ID NO.27 forms, the sequence that formed by SEQ ID NO.5 and SEQ ID NO.28 in one or more; For the sequence being formed by SEQ ID NO.6 and SEQ ID NO.29 in E69K site and the sequence that formed by SEQ ID NO.7 and SEQ ID NO.30; For the sequence being formed by SEQ IDNO.8 and SEQ ID NO.31 in A72T/D site and select free SEQ ID NO.9 and sequence that SEQ ID NO.32 forms, the sequence that formed by SEQ ID NO.10 and SEQ ID NO.33 in one or more; For the sequence being formed by SEQ ID NO.11 and SEQ ID NO.34 in T73I site and the sequence that formed by SEQ ID NO.12 and SEQ ID NO.35; For the sequence being formed by SEQ ID NO.13 and SEQ ID NO.36 in E76K/Q/A/G/V site and select the sequence that free SEQ ID NO.14 and SEQID NO.37 form, the sequence being formed by SEQ ID NO.15 and SEQ ID NO.38, the sequence being formed by SEQ ID NO.16 and SEQID NO.39, the sequence being formed by SEQ ID NO.17 and SEQ ID NO.40, one or more in the sequence that formed by SEQ ID NO.18 and SEQID NO.41; For the sequence being formed by SEQ ID NO.19 and SEQ ID NO.42 in S502P site and the sequence that formed by SEQ ID NO.20 and SEQ ID NO.43; And/or for the sequence being formed by SEQ IDNO.21 and SEQ ID NO.44 in G503A/V site and select free SEQ ID NO.22 and sequence that SEQ ID NO.45 forms, the sequence that formed by SEQ ID NO.23 and SEQ ID NO.46 in one or more.
Another object of the present invention is to provide the Auele Specific Primer for PTPN11 detection in Gene Mutation.
Concrete technical scheme is as follows: described specific primer sequence is: for SEQ IDNO.24 and the SEQ IDNO.25 in G60V site; For the SEQ ID NO.26 in D61Y/V site and be selected from one or more in SEQ ID NO.27, SEQ ID NO.28; For SEQ ID NO.29 and the SEQ ID NO.30 in E69K site; For the SEQ ID NO.31 in A72T/D site and be selected from one or more in SEQ ID NO.32, SEQ ID NO.33; For SEQ ID NO.34 and the SEQ IDNO.35 in T73I site; For the SEQ ID NO.36 in E76K/Q/A/G/V site and be selected from one or more in SEQ ID NO.37, SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40, SEQ ID NO.41; For SEQ ID NO.42 and the SEQ ID NO.43 in S502P site; And/or for the SEQ ID NO.44 in G503A/V site and be selected from one or more in SEQ ID NO.45, SEQ IDNO.46.
Major advantage of the present invention is:
1. the identical rate of detection method provided by the present invention and sequencing is up to 100%, and detects the needed time well below conventional sequencing technologies, and realistic especially application needs.Prepared PTPN11 gene mutation detection liquid-phase chip has extraordinary signal-noise ratio, and between designed probe and anti-tag sequence, substantially there is not cross reaction, choosing and tag sequence label and the specifically combination of ASPE primer of tag sequence label, anti-tag sequence label, can avoid cross reaction, realize the parallel detection in multiple mutational sites.
2. the present invention, by the design experiences of the long-term accumulation of contriver and a large amount of experimental implementation, has chosen optimum combination from numerous Auele Specific Primers.The ASPE primer specificity primer of the present invention design can the sensitive mutational site of identifying specifically target detect, accurately distinguishes the genotype of various types; In same reaction system, between different Auele Specific Primers, substantially there is not cross reaction between Auele Specific Primer and the pcr amplification product of non-target detect, detection specificity is good, and cross reacting rate is lower than 3%; Except detecting Single locus sudden change situation, the also sudden change situation in the multiple mutational sites of parallel detection simultaneously, detects effect consistent.
3. detection method step of the present invention is simple, the amplification that can complete by a step PCR 2 target sequences that contain mutational site is detected in 15 kinds of mutational sites, the many uncertain factors that exist in the complex operations processes such as repeated multiple times PCR are avoided, thereby can greatly improve Detection accuracy, embody accurate while qualitative and quantitative analysis feature.
4. not only to have overcome traditional solid phase chip susceptibility not high in the present invention, and the poor defect of repeatability of detected result is improved existing liquid-phase chip technology simultaneously, makes prepared microballoon can be applicable to different test items, has very strong expansion.The fluorescent signal value detecting improves greatly, thereby the sensitivity detecting is further enhanced, and signal to noise ratio strengthens, and detected result more accurately and reliably.
Embodiment
Embodiment 1
PTPN11 gene mutation detection liquid-phase chip described in this enforcement 1, mainly includes:
One, ASPE primer
For wild-type type and the saltant type of 15 kinds of common genotype G60V, D61Y/V of 8 codons of PTPN11 gene, E69K, A72T/D, T73I, E76K/Q/A/G/V, S502P, G503A/V, design respectively specific primer sequence.ASPE primer is made up of " tag sequence+specific primer sequence ".ASPE primer sequence is as shown in the table:
The ASPE primer sequence (tag sequence+specific primer sequence) of table 1PTPN11 gene
Every ASPE primer comprises two parts, and 5 ' end is the specificity tag sequence for anti-tag sequence on corresponding microballoon, and 3 ' end is saltant type or the special primer fragment (as shown in Table 1 above) of wild-type.All ASPE primers are synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Two, the coated microballoon of anti-tag sequence
According to designed ASPE Auele Specific Primer fragment, select tag sequence, reduce to greatest extent between the anti-tag sequence of each microballoon and secondary structure that tag and ASPE Auele Specific Primer fragment may form, on 23 kinds of microballoons numberings of selection and microballoon, corresponding anti-tag sequence is as shown in table 2:
Corresponding anti-tag sequence on table 2 microballoon numbering and microballoon
23 kinds of microballoons selecting, purchased from Luminex company of the U.S., are coated in anti-tag sequence on microballoon.Between anti-tag sequence and microballoon, be connected with the spacerarm sequence of 5-10 T, before each anti-tag sequence, add the spacerarm sequence of the preceding paragraph 5-10 T, anti-tag sequence is synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.By synthetic anti-tag sequence sterilizing ddH
2o is made into the stock solution of 100nmol/ml.Described spacerarm is for by anti-tag and microsphere surface is spaced apart or anti-tag is placed in to the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between anti-tag sequence and microballoon, can reduce sterically hinderedly, improve the efficiency of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n >=3), as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-10 T, and the coated process of microballoon is as follows:
Get respectively 5 × 10
6the carboxylated microballoon (purchased from Luminex company) of individual above-mentioned numbering is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds the synthetic anti-tag molecule (100nmol/ml) of 10ul.EDC (N-(3-Dimethylaminopropyl-N-ethylcarbodiimide) (purchased from the Pierce Chemical company) working fluid of preparation 10ng/ml.Toward the EDC working fluid that adds 2.5ul in microballoon suspension, constant-temperature incubation 30 minutes, then add the EDC working fluid of 2.5ul, then constant-temperature incubation 30 minutes.After reaction finishes, the Tween-20 with 0.02% washs once, then washs once with 0.1% SDS liquid.The Tris-EDTA solution [10mmol/L Tris (pH8.0)] that the microballoon that is coated with anti-tag sequence after washing is resuspended in to 100ul, in 1mmol/LEDTA, 2-8 DEG C keeps in Dark Place.
Three, amplify the primer of the target sequence that contains mutational site
For 15 kinds of common genotype G60V, D61Y/V, E69K, A72T/D, T73I, E76K/Q/A/G/V, S502P, the G503A/V of 8 codons of PTPN11 gene, design of amplification primers, to (in table 3), amplifies 2 target sequences that contain mutational site.
Table 3 amplifies the primer of the target sequence with mutational site
All primers are synthesized by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Embodiment 2 uses the detection to sample of PTPN11 gene mutation detection liquid-phase chip described in embodiment 1
The formula of described various solution is as follows:
MES damping fluid (pH5.0) formula (250ml) of 50mM:
2 × Tm hybridization buffer
| Reagent | Source | Final concentration | The consumption of every 250ml |
| 1MTris-HCl，pH8.0 | Sigma T3038 | 0.2M | 50ml |
| 5MNaCl | Sigma S5150 | 0.4M | 20ml |
| Triton X-100 | Sigma T8787 | 0.16％ | 0.4ml |
After filtration, be stored in 4 DEG C.
ExoSAP-IT test kit is purchased from USB company of the U.S..
Biotin labeled dCTP is purchased from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
One, the DNA extraction of sample:
Methods involving with reference to " molecular cloning " about DNA extraction, obtains DNA to be detected.
Two, the pcr amplification of testing sample
Design 2 pairs of primers, multiplex PCR one step amplifies 15 kinds of common genotype G60V, the D61Y/V, E69K, A72T/D, T73I, E76K/Q/A/G/V, S502P, the G503A/V that contain respectively 8 codons of PTPN11 gene, wherein, G60V, D61Y/V, E69K, A72T/D, T73I and E76K/Q/A/G/V are positioned at same amplified production, S502P and G503A/V are positioned at same amplified production, product size is respectively 367bp and 407bp, and primer sequence (SEQ ID NO.70-73) is shown in shown in above-mentioned table 3.
First prepare multiple PCR primer working fluid: respectively get respectively the primer stock solution 100ul of SEQ ID NO.70-73 in 1.5ml Eppendorf tube, mix and be multiple PCR primer working fluid.Multi-PRC reaction system is as follows:
Pcr amplification program is: 95 DEG C of 3min; 94 DEG C of 30s, 56 DEG C of 30s, 72 DEG C of 40s, 30 circulations; 72 DEG C of 10min; 4 DEG C save backup.
Three, the enzyme of PCR product is cut processing
1. get the reacted product of 7.5ul PCR, add 1ul 10 × SAP damping fluid, 1ul SAP enzyme and 0.5ul Exo-I enzyme;
Hatch 15min for 2.37 DEG C, hatch 15min for 80 DEG C, the enzyme that deactivation is unnecessary.Enzyme is cut product after treatment and is directly used in follow-up ASPE primer extension reaction.
Four, site-specific primer extension reaction (ASPE)
Utilize the ASPE primer of above-mentioned design to carry out primer extension reaction, in reaction process, mix biotin labeled dCTP, thereby make multiple biotin labeling on reacted product band.
First the ASPE primer working fluid that preparation mixes: get respectively the corresponding wild-type of gene to be detected and saltant type ASPE primer stock solution 10ul in 1.5ml Eppendorf tube, add 10mmol/L Tris Buffer to mend to 200ul, mix and be ASPE mix primer working fluid.The system of ASPE reaction is as follows:
Response procedures is: 96 DEG C of 2min; 94 DEG C of 30s, 54 DEG C of 1min, 72 DEG C of 2min, 30 circulations; 4 DEG C save backup.
Five, hybridization
According to design ASPE primer, the corresponding 23 kinds of coated microballoons of every group selection (as described in Example 1), every kind of microballoon concentration is 2.5 × 10
5individual/ml;
2. get respectively the microballoon of every kind of numbering of 1ul in the Eppendorf tube of 1.5ml;
3. microballoon is in >=centrifugal the 1-2min of 10000g;
4. supernatant discarded, microballoon is resuspended in 2 × Tm hybridization buffer of 100ul, and vortex mixes;
5. get the above-mentioned microballoon suspension of 25ul in the 96 corresponding holes of hole filter plate, control wells adds the ddH of 25ul
2o;
6. get the ASPE reaction solution of 5-25ul in corresponding hole, use ddH
2o complements to 50ul;
7. encase 96 orifice plates with lucifuge with masking foil, 95 DEG C of 60s, 37 DEG C of 15min are hatched hybridization;
8. the microballoon after hybridization is in >=centrifugal the 2-5min of 3000g;
9. remove supernatant, microballoon is resuspended in 1 × Tm hybridization buffer of 75ul;
10. microballoon is in >=centrifugal the 2-5min of 3000g;
11. are resuspended in microballoon in 1 × Tm hybridization buffer of 75ul, and adding 15ul concentration is the SA-PE (SA-PE) of 10ug/ml;
Hatch 15min for 12.37 DEG C, on Luminex instrument, detect.
Six, result detects and data analysis
Reaction after product detects by Luminex serial analysis instrument.Be greater than 100 as cut-off values taking saltant type fluorescent value (MFI), in the time that the MFI value of saltant type detection is greater than 100, judges that this sample exists this mutation type, otherwise judge that this sample is as corresponding wild-type.
Use present method to detect the PTPN11 transgenation of great amount of samples, detect with liquid-phase chip result and compare with sequencing, calculate the identical rate of method detected result provided by the present invention.Present method detects 20 increments PTPN11 genotype detection result and the sequencing result rate of coincideing originally and reaches 100%.Visible PTPN11 gene mutation detection liquid-phase chip provided by the present invention can detect the mutation type of PTPN11 gene exactly, and result is reliable and stable.
One of table 4 pattern detection result (MFI)
Two of table 5 pattern detection result (MFI)
Three of table 6 pattern detection result (MFI)
Table 7 sample PTPN11 gene mutation type analytical results
| Catalogue number(Cat.No.) | Liquid-phase chip detected result | Sequencing result |
| 1 | Wild-type | Wild-type |
| 2 | E69K sudden change | E69K sudden change |
| 3 | Wild-type | Wild-type |
| 4 | G503V sudden change | G503V sudden change |
| 5 | Wild-type | Wild-type |
| 6 | G60V, T73I sudden change | G60V, T73I sudden change |
| 7 | Wild-type | Wild-type |
| 8 | Wild-type | Wild-type |
| 9 | Wild-type | Wild-type |
| 10 | Wild-type | Wild-type |
| 11 | Wild-type | Wild-type |
| 12 | Wild-type | Wild-type |
| 13 | E76A sudden change | E76A sudden change |
| 14 | Wild-type | Wild-type |
| 15 | D61Y sudden change | D61Y sudden change |
| 16 | Wild-type | Wild-type |
| 17 | A72D sudden change | A72D sudden change |
| 18 | Wild-type | Wild-type |
| 19 | Wild-type | Wild-type |
| 20 | Wild-type | Wild-type |
The detection of the liquid-phase chip of the ASPE primer that embodiment 3 is different to PTPN11 gene mutation site
One, the design (selection of Tag sequence and Anti-Tag sequence) that prepared by liquid-phase chip
Detect liquid-phase chip as example taking PTPN11 gene G60V and E69K site mutation, respectively for the wild-type of G60V and E69K and the specific primer sequence of saltant type design ASPE primer 3 ' end, the Tag sequence of ASPE primer 5 ' end is selected from SEQ ID NO.1-SEQ ID NO.23, accordingly, the anti-tag sequence with corresponding tag sequence complementary pairing being coated on microballoon is selected from SEQ ID NO.47-SEQ ID NO.69.Specific design is as shown in following table (table 8).Synthetic, the anti-tag sequence of ASPE primer are coated with microballoon, amplimer, detection method etc. as described in embodiment 1 and embodiment 2.
Design prepared by table 8 liquid-phase chip
Two, sample detection
The liquid-phase chip that adopts above-mentioned design to prepare, detects sample 21-40 by testing process described in embodiment 2 and method, and detected result is as follows:
Table 9 pattern detection result and gene mutation analysis
Table 10 pattern detection result and gene mutation analysis
From the present embodiment, when ASPE primer is selected in embodiment 1 collocation of tag sequence and specific primer sequence, effect better (signal to noise ratio is better), referring to the present embodiment test group 1 and test group 5.Other different tag sequences and specific primer sequence collocation, with coming to the same thing of embodiment 2 and the present embodiment, concrete data are omitted.
Other is for the liquid-phase chip in different mutational sites, ASPE primer uses different Tag sequences, and its result is still reliable and stable, and ASPE primer is while selecting in embodiment 1 collocation of tag sequence and specific primer sequence, effect better (signal to noise ratio is better), concrete data are omitted.
The selection of embodiment 4PTPN11 detection in Gene Mutation specific primer sequence
One, the design (selection of wild-type and saltant type specific primer sequence) that prepared by liquid-phase chip
Detect liquid-phase chip as example taking the mutational site of PTPN11 Gene A 72T/D and S502P, taking the complementary sequence forward or backwards of this place, mutational site target sequence as template, respectively for the wild-type of A72T/D and S502P and the specific primer sequence of saltant type design ASPE primer 3 ' end, comprise preferred specific primer sequence and 2 alternative specific primer sequences in the embodiment of the present invention 1, as shown in table 11.Wherein,
interior base is mutational site.
Table 11 specific primer sequence
Detect liquid-phase chip as example taking the mutational site of PTPN11 gene G12C and Q61K, select different specific primer sequences for G12C and Q61K, the Tag sequence of ASPE primer 5 ' end is fixed as the best effect sequence in embodiment 1, and select the anti-tag sequence of answering in contrast, specific design is as shown in following table (table 12).Synthetic, the anti-tag sequence of ASPE primer are coated with microballoon, amplimer, detection method etc. as described in embodiment 1 and embodiment 2.
Two of design prepared by table 12 liquid-phase chip
Two, sample detection
The liquid-phase chip that adopts above-mentioned design to prepare, detects sample 41-60 by testing process described in embodiment 2 and method, and detected result is as follows:
Table 13 pattern detection result and gene mutation analysis
Table 14 pattern detection result and gene mutation analysis
From the present embodiment, when ASPE primer is selected in embodiment 1 collocation of specific primer sequence and tag sequence, effect better (signal to noise ratio is better), referring to the present embodiment test group 7 and test group 10.Other derives from different specific primer sequences and the collocation of tag sequence of the complementary sequence forward or backwards of place, target detect site sequence, with coming to the same thing of embodiment 2 and the present embodiment, be still that the specific primer sequence described in embodiment 1 is better from different tag sequence arranging effects, concrete data are omitted.
The multiple specific primer sequence in other multiple specific primer sequence for identical mutation site or different mutational site and the collocation of tag sequence, with coming to the same thing of embodiment 2 and the present embodiment, it is the selected Auele Specific Primer of embodiment 1, there is better signal to noise ratio, detect effect also better, concrete data are omitted.
Be more than for the illustrating of possible embodiments of the present invention, but this embodiment is not in order to limit the scope of the claims of the present invention, allly do not depart from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the scope of the claims of the present invention.
Claims (5)
1. a PTPN11 gene mutation detection liquid-phase chip, is characterized in that, includes:
(A). the wild-type designing respectively for the different mutational sites of PTPN11 gene and the ASPE primer of saltant type: every kind of ASPE primer is made up of for the specific primer sequence in goal gene mutational site tag sequence and the 3 ' end of 5 ' end, and described specific primer sequence is: for SEQ ID NO.24 and the SEQ ID NO.25 in G60V site; For the SEQ ID NO.26 in D61Y/V site and be selected from SEQ ID NO.27 and SEQ ID NO.28 in one or more; For SEQ ID NO.29 and the SEQ ID NO.30 in E69K site; For the SEQ ID NO.31 in A72T/D site and be selected from SEQ ID NO.32 and SEQ ID NO.33 in one or more; For SEQ ID NO.34 and the SEQ ID NO.35 in T73I site; For the SEQ ID NO.36 in E76K/Q/A/G/V site and be selected from one or more in SEQ ID NO.37, SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40 and SEQ ID NO.41; For SEQ ID NO.42 and the SEQ ID NO.43 in S502P site; And/or for the SEQ ID NO.44 in G503A/V site and be selected from SEQ ID NO.45 and SEQ ID NO.46 in one or more; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.23;
(B). there is microballoon that anti-tag sequence is coated with, that there is different colours coding, in the middle of described anti-tag sequence is connected with microballoon, be also provided with spacerarm sequence; Described anti-tag sequence is selected from SEQ ID NO.47～SEQ ID NO.69, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). for amplifying the primer that needs the target sequence detecting, there is corresponding mutational site,
Described amplimer is: for SEQ ID NO.70～SEQ ID NO.71 in G60V, D61Y/V, E69K, A72T/D, T73I, E76K/Q/A/G/V site; And/or for SEQ ID NO.72～SEQ ID NO.73 in S502P, G503A/V site.
2. PTPN11 gene mutation detection liquid-phase chip according to claim 1, it is characterized in that, described ASPE primer is: the sequence forming for the sequence being made up of SEQ ID NO.1 and SEQ ID NO.24 in G60V site and SEQ ID NO.2 and SEQ ID NO.25; For the sequence being formed by SEQ ID NO.3 and SEQ ID NO.26 in D61Y/V site and select free SEQ ID NO.4 and sequence that SEQ ID NO.27 forms, the sequence that formed by SEQ ID NO.5 and SEQ ID NO.28 in one or more; For the sequence being formed by SEQ ID NO.6 and SEQ ID NO.29 in E69K site and the sequence that formed by SEQ ID NO.7 and SEQ ID NO.30; For the sequence being formed by SEQ ID NO.8 and SEQ ID NO.31 in A72T/D site and select free SEQ ID NO.9 and sequence that SEQ ID NO.32 forms, the sequence that formed by SEQ ID NO.10 and SEQ ID NO.33 in one or more; For the sequence being formed by SEQ ID NO.11 and SEQ ID NO.34 in T73I site and the sequence that formed by SEQ ID NO.12 and SEQ ID NO.35; For the sequence being formed by SEQ ID NO.13 and SEQ ID NO.36 in E76K/Q/A/G/V site and select free SEQ ID NO.14 and the sequence that SEQ ID NO.37 forms, the sequence being formed by SEQ ID NO.15 and SEQ ID NO.38, the sequence being formed by SEQ ID NO.16 and SEQ ID NO.39, the sequence being formed by SEQ ID NO.17 and SEQ ID NO.40, the sequence that formed by SEQ ID NO.18 and SEQ ID NO.41 in one or more; For the sequence being formed by SEQ ID NO.19 and SEQ ID NO.42 in S502P site and the sequence that formed by SEQ ID NO.20 and SEQ ID NO.43; And/or for the sequence being formed by SEQ ID NO.21 and SEQ ID NO.44 in G503A/V site and select free SEQ ID NO.22 and sequence that SEQ ID NO.45 forms, the sequence that formed by SEQ ID NO.23 and SEQ ID NO.46 in one or more.
3. PTPN11 gene mutation detection liquid-phase chip according to claim 1, is characterized in that:
(A). described ASPE primer is: the sequence forming for the sequence being made up of SEQ ID NO.1 and SEQ ID NO.24 in G60V site and SEQ ID NO.2 and SEQ ID NO.25; For the sequence being formed by SEQ ID NO.3 and SEQ ID NO.26 in D61Y/V site and the sequence being formed by SEQ ID NO.4 and SEQ ID NO.27 and the sequence that formed by SEQ ID NO.5 and SEQ ID NO.28; For the sequence being formed by SEQ ID NO.6 and SEQ ID NO.29 in E69K site and the sequence that formed by SEQ ID NO.7 and SEQ ID NO.30; For the sequence being formed by SEQ ID NO.8 and SEQ ID NO.31 in A72T/D site and the sequence being formed by SEQ ID NO.9 and SEQ ID NO.32 and the sequence that formed by SEQ ID NO.10 and SEQ ID NO.33; For the sequence being formed by SEQ ID NO.11 and SEQ ID NO.34 in T73I site and the sequence that formed by SEQ ID NO.12 and SEQ ID NO.35; For the sequence being formed by SEQ ID NO.13 and SEQ ID NO.36 in E76K/Q/A/G/V site and the sequence being formed by SEQ ID NO.14 and SEQ ID NO.37, the sequence being formed by SEQ ID NO.15 and SEQ ID NO.38, the sequence being formed by SEQ ID NO.16 and SEQ ID NO.39, the sequence being formed by SEQ ID NO.17 and SEQ ID NO.40 and the sequence that formed by SEQ ID NO.18 and SEQ ID NO.41; For the sequence being formed by SEQ ID NO.19 and SEQ ID NO.42 in S502P site and the sequence that formed by SEQ ID NO.20 and SEQ ID NO.43; With the sequence being formed by SEQ ID NO.21 and SEQ ID NO.44 for G503A/V site and the sequence being formed by SEQ ID NO.22 and SEQ ID NO.45 and the sequence that formed by SEQ ID NO.23 and SEQ ID NO.46;
(B). there is microballoon that anti-tag sequence is coated with, that there is different colours coding, in the middle of described anti-tag sequence is connected with microballoon, be also provided with spacerarm sequence; Described anti-tag sequence is selected from SEQ ID NO.47～SEQ ID NO.69, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). described amplimer is: for SEQ ID NO.70～SEQ ID NO.71 in G60V, D61Y/V, E69K, A72T/D, T73I, E76K/Q/A/G/V site; With the SEQ ID NO.72～SEQ ID NO.73 for S502P, G503A/V site.
4. according to the PTPN11 gene mutation detection liquid-phase chip described in claim 1-3 any one, it is characterized in that, described spacerarm is 5-10 T.
5. for the Auele Specific Primer of PTPN11 detection in Gene Mutation liquid, it is characterized in that, described specific primer sequence is: for SEQ ID NO.24 and the SEQ ID NO.25 in G60V site; For the SEQ ID NO.26 in D61Y/V site and be selected from SEQ ID NO.27 and SEQ ID NO.28 in one or more; For SEQ ID NO.29 and the SEQ ID NO.30 in E69K site; For the SEQ ID NO.31 in A72T/D site and be selected from SEQ ID NO.32 and SEQ ID NO.33 in one or more; For SEQ ID NO.34 and the SEQ ID NO.35 in T73I site; For the SEQ ID NO.36 in E76K/Q/A/G/V site and be selected from one or more in SEQ ID NO.37, SEQ ID NO.38, SEQ ID NO.39, SEQ ID NO.40 and SEQ ID NO.41; For SEQ ID NO.42 and the SEQ ID NO.43 in S502P site; And/or for the SEQ ID NO.44 in G503A/V site and be selected from SEQ ID NO.45 and SEQ ID NO.46 in one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110269795.2A CN102994621B (en) | 2011-09-13 | 2011-09-13 | PTPN11 gene mutation detection specificity primer and liquid chip thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110269795.2A CN102994621B (en) | 2011-09-13 | 2011-09-13 | PTPN11 gene mutation detection specificity primer and liquid chip thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102994621A CN102994621A (en) | 2013-03-27 |
| CN102994621B true CN102994621B (en) | 2014-12-10 |
Family
ID=47923727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110269795.2A Expired - Fee Related CN102994621B (en) | 2011-09-13 | 2011-09-13 | PTPN11 gene mutation detection specificity primer and liquid chip thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102994621B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104531862B (en) * | 2014-12-19 | 2017-12-29 | 钱学庆 | Detect the method and primer in the full exon sequence mutational site of mankind's BRCA1 and BRCA2 gene |
| CN110804658A (en) * | 2019-10-16 | 2020-02-18 | 北京艾迪康医学检验实验室有限公司 | Method, primer and kit for detecting PTPN11 gene mutation |
| WO2021213479A1 (en) * | 2020-04-22 | 2021-10-28 | 复星凯特生物科技有限公司 | Shp2 specific inactivating mutant protein and application thereof in car-t therapy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550262B2 (en) * | 2002-11-05 | 2009-06-23 | Mount Sinai School Of Medicine Of New York University | PTPN11 (SHP-2) mutations and cancer |
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
-
2011
- 2011-09-13 CN CN201110269795.2A patent/CN102994621B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550262B2 (en) * | 2002-11-05 | 2009-06-23 | Mount Sinai School Of Medicine Of New York University | PTPN11 (SHP-2) mutations and cancer |
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102994621A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102994619B (en) | NRAS gene mutation detection specificity primer and liquid chip thereof | |
| CN102994621B (en) | PTPN11 gene mutation detection specificity primer and liquid chip thereof | |
| CN102134605B (en) | Single-nucleotide polymorphism (SNP) detection specific primer of CYP2C19 gene and liquid phase chip | |
| CN103031370B (en) | RB1 gene mutation detection specific primer and liquid chip | |
| CN103374609B (en) | ABO gene mutation detection specific primers and liquid chip | |
| CN102912002B (en) | ABCB2 gene polymorphism detection specific primers and liquid chip | |
| CN103031365B (en) | ATM gene mutation detection specific primer and liquid chip | |
| CN103031369B (en) | CDKN2A gene mutation detection specific primer and liquid chip | |
| CN102191337B (en) | Specific primers and liquid phase chip for detecting polymorphism of cyckin-dependent kinase 5 regulatorysubunit-associated protein 1-like 1(CDKAL1) gene | |
| CN103031364B (en) | FGFR3 gene mutation detection specific primer and liquid chip | |
| CN103374607B (en) | ABCC (ATP (adenosine triphosphate)-binding cassette, sub-family C)1 gene mutation detection specific primers and liquid chip | |
| CN103031367A (en) | VHL (Von Hippel Lindau) genetic mutation detection specific primer and liquid phase chip | |
| CN102994616B (en) | MEK1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102952866B (en) | Specific primer and liquid chip for detecting polymorphism of DPYD (dihydropyrimidine dehydrogenase) gene | |
| CN102994623B (en) | STK11 gene mutation detection specificity primer and liquid chip thereof | |
| CN102994625B (en) | PIK3R1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102181573B (en) | Specific primers and liquid-phase chip for detection of KITLG gene | |
| CN103031368B (en) | FGFR1 gene mutation detection specific primer and liquid chip | |
| CN102559850B (en) | ApoA5 genic mutation detection specific primer and liquid phase chip | |
| CN102994620B (en) | AKT1 gene mutation detection specificity primer and liquid chip thereof | |
| CN103031371B (en) | CDH1 gene mutation detection specific primer and liquid chip | |
| CN103031366B (en) | FGFR2 gene mutation detection specific primer and liquid chip | |
| CN102888444B (en) | Factor II and Factor V genetic polymorphism detection specific primer and liquid-phase chip | |
| CN102191335B (en) | Specific primer and liquid-phase chip for SNP (single nucleotide polymorphism) detection of PIGU (phosphatidylinositol glycan anchor biosynthesis, class U) genes | |
| CN102952870B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A2 gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant after: SUREXAM BIO-TECH Co.,Ltd. Address before: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant before: GUANGZHOU SUREXAM BIO-TECH Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGZHOU YISHAN BIOTECHNOLOGY CO., LTD. TO: SUREXAM BIOTECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141210 |